Search results
Results from the Health.Zone Content Network
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange.
GSK and Pfizer merged their consumer healthcare businesses in 2019. [8] [9] GSK owned just over two thirds of the joint venture, and Pfizer held the remainder.[8]GSK announced plans to spin-off Haleon in 2018, in order to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division".
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs , primarily for skin diseases , gastrointestinal disorders , eye health ...
Mallinckrodt Pharmaceuticals plc is an American-Irish domiciled manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it generated 90% of its sales from the U.S. healthcare system.
In 2001 the company acquired Biochem Canada. [9] Shire's next acquisition didn't come until 2005 when it acquired Transkaryotic Therapeutics [10] and two years later – in 2007 – New River Pharmaceuticals Inc, for a then company record of $2.6 billion. [11]
Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom.It was formed in June 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries into a separate company listed on the London Stock Exchange.
On 1 October 2013, Gildemeister Aktiengesellschaft became DMG Mori Seiki Aktiengesellschaft. Mori Seiki changed its name to DMG Mori Seiki Company Limited. On the global market, both companies used the DMG MORI brand. On 21 January 2015, the DMG Mori Seiki Aktiengesellschaft signed another cooperation agreement with DMG Mori Seiki Co., Ltd.
Michael Jaharis and Frost bought Key Pharmaceuticals, Inc. in 1972. Frost was chairman of the board of directors of Key Pharmaceuticals, from 1972, until its acquisition by Schering-Plough in 1986, for $835 million. [5] Frost's share was $100 million. [6] Frost's estimated net worth in 1986 was $150 million. [7]